Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (nait)

Abstract

A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.

1 - 17 . (canceled) 
     
     
         18 . A preparation useful in inhibiting an immune response to human platelet antigen HPA 1a, the preparation comprising an Immunoglobulin G (IgG) concentrate containing antibodies specific to human platelet antigen HPA 1a. 
     
     
         19 . The preparation as claimed in  claim 18 , wherein the IgG concentrate is derived from human plasma. 
     
     
         20 . The preparation as claimed in  claim 18 , wherein the preparation comprises 100-400 μg anti-HPA 1a antibodies. 
     
     
         21 . The preparation as claimed in  claim 20 , wherein the preparation comprises 200-300 μg anti-HPA 1a antibodies. 
     
     
         22 . The preparation as claimed in  claim 18 , wherein the preparation comprises 50-200 μg/ml anti-HPA 1a antibodies. 
     
     
         23 . The preparation as claimed in  claim 18 , wherein the preparation comprises 66-266 μg/ml anti-HPA 1a antibodies. 
     
     
         24 . The preparation as claimed in  claim 23 , wherein the preparation comprises 100-150 μg/ml anti-HPA 1a antibodies. 
     
     
         25 . The preparation as claimed in  claim 23 , wherein the preparation comprises 133-200 μg/ml anti-HPA 1a antibodies. 
     
     
         26 . The preparation as claimed in  claim 18 , wherein the preparation comprises 200-800 μg/ml anti-HPA 1a antibodies. 
     
     
         27 . The preparation as claimed in  claim 26 , wherein the preparation comprises 400-600 μg/ml anti-HPA 1a antibodies. 
     
     
         28 . A method for the production of a preparation useful in the prophylactic treatment of NAIT, the method comprising the steps of:
 a. Identifying blood plasma donors having HPA 1a antibodies,   b. Collecting plasma from the donors, and   c. Fractionating IgG from the plasma   wherein the fractionated IgG is aliquoted into dosages comprising:   (i) 100-400 μg anti-HPA 1a antibodies, or   (ii) 50-200 μg/ml anti-HPA 1a antibodies, or   (iii) 200-800 μg/ml anti-HPA 1a antibodies.